{
  "metadata": {
    "created": "2026-01-30",
    "last_updated": "2026-01-30",
    "total_months": 3,
    "starting_capital": 100000
  },
  "current_portfolio": [
    {
      "ticker": "GLD",
      "company_name": "SPDR Gold Shares",
      "asset_class": "commodity_etf",
      "sector": "Metals",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "hedge",
      "risk_level": "conservative",
      "time_horizon": "long_term",
      "allocation_pct": 10,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 421.04,
      "entry_zone": {
        "low": 421.04,
        "high": 442.74
      },
      "price_target": 504.72,
      "stop_loss": 383.59,
      "thesis": "Gold is surging (+9.6% 1mo) in a weakening dollar environment with persistent inflation. Central bank buying continues unabated globally, and real rates remain historically low. With S&P valuations stretched at 27.86x P/E, gold serves as essential portfolio insurance. The breakout above prior resistance suggests momentum continuation toward $500.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "XOM",
      "company_name": "Exxon Mobil Corporation",
      "asset_class": "us_stock",
      "sector": "Energy",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "value",
      "risk_level": "moderate",
      "time_horizon": "medium_term",
      "allocation_pct": 10,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 134.17,
      "entry_zone": {
        "low": 134.17,
        "high": 141.09
      },
      "price_target": 167.47,
      "stop_loss": 119.09,
      "thesis": "Energy is the strongest sector (+11.3% 1mo, RS +13.8) with oil at $77.82 (+11.6%). XOM offers best-in-class capital discipline, 3%+ dividend yield, and premier Permian/Guyana assets. The company's $60B+ Permian acquisition creates unmatched scale advantages. In an inflationary regime, integrated majors historically outperform. Share buybacks provide downside support.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "FCX",
      "company_name": "Freeport-McMoRan Inc.",
      "asset_class": "us_stock",
      "sector": "Materials",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "growth",
      "risk_level": "aggressive",
      "time_horizon": "medium_term",
      "allocation_pct": 7,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 57.27,
      "entry_zone": {
        "low": 57.27,
        "high": 60.22
      },
      "price_target": 78.72,
      "stop_loss": 48.54,
      "thesis": "Copper is the standout commodity (+14.6% 1mo) driven by AI data center power demand and EV adoption. FCX is the largest publicly traded copper producer with premium assets (Grasberg). Supply deficits are structural as new mine development lags. Materials sector strength (RS +12.6) confirms institutional rotation. The electrification megatrend makes copper the new oil.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "KO",
      "company_name": "Coca-Cola Company",
      "asset_class": "us_stock",
      "sector": "Consumer Staples",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "dividend",
      "risk_level": "conservative",
      "time_horizon": "long_term",
      "allocation_pct": 10,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 72.02,
      "entry_zone": {
        "low": 72.02,
        "high": 75.73
      },
      "price_target": 85.87,
      "stop_loss": 65.66,
      "thesis": "KO just hit a 52-week high breakout at $73.98, confirming consumer staples leadership (+5.6% 1mo). This is the ultimate defensive compounder with 60+ consecutive years of dividend increases. Pricing power remains intact, and international markets drive growth. In an expensive market with elevated uncertainty, KO provides stability and income. 3%+ dividend yield with growth.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "ISRG",
      "company_name": "Intuitive Surgical Inc.",
      "asset_class": "us_stock",
      "sector": "Healthcare",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "garp",
      "risk_level": "moderate",
      "time_horizon": "long_term",
      "allocation_pct": 8,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 489.12,
      "entry_zone": {
        "low": 489.12,
        "high": 514.34
      },
      "price_target": 622.16,
      "stop_loss": 441.53,
      "thesis": "ISRG is severely oversold (RSI 7.2) presenting a rare buying opportunity in the undisputed leader of surgical robotics. The da Vinci platform has an installed base of 9,000+ systems globally with 80%+ market share. Recurring revenue from instruments and services provides stability. Healthcare is defensive, and robotic surgery adoption is a secular tailwind. The technical setup screams capitulation.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "GSK",
      "company_name": "GSK plc",
      "asset_class": "international_stock",
      "sector": "Healthcare",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "value",
      "risk_level": "moderate",
      "time_horizon": "medium_term",
      "allocation_pct": 8,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 49.84,
      "entry_zone": {
        "low": 49.84,
        "high": 52.41
      },
      "price_target": 63.08,
      "stop_loss": 44.77,
      "thesis": "GSK broke to 52-week highs at $51.31 signaling institutional accumulation. Post-Haleon spin-off, GSK is a focused biopharma with a rebuilt pipeline. Trading at ~10x forward earnings with a 4%+ dividend yield, valuation is compelling vs US healthcare peers. The RSV vaccine Arexvy is a blockbuster, and oncology pipeline has multiple near-term readouts. International diversification at a discount.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "BRK-B",
      "company_name": "Berkshire Hathaway Inc. Class B",
      "asset_class": "us_stock",
      "sector": "Financials",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "value",
      "risk_level": "conservative",
      "time_horizon": "long_term",
      "allocation_pct": 10,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 464.95,
      "entry_zone": {
        "low": 464.95,
        "high": 488.92
      },
      "price_target": 563.92,
      "stop_loss": 420.37,
      "thesis": "Berkshire is the ultimate all-weather holding. Buffett has accumulated $300B+ in cash/Treasuries earning 5%+, suggesting patience amid expensive markets. Insurance operations generate float for investment, while wholly-owned businesses (BNSF, BHE) provide stability. Zero dividend means tax-efficient compounding. This is a diversified conglomerate in one stock - perfect for an uncertain environment.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "TIP",
      "company_name": "iShares TIPS Bond ETF",
      "asset_class": "bond_etf",
      "sector": "Fixed Income",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "hedge",
      "risk_level": "conservative",
      "time_horizon": "medium_term",
      "allocation_pct": 7,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 107.14,
      "entry_zone": {
        "low": 107.14,
        "high": 112.66
      },
      "price_target": 123.3,
      "stop_loss": 100.69,
      "thesis": "In an inflationary regime, TIPS (Treasury Inflation-Protected Securities) provide principal protection against CPI increases. With commodities surging across the board and the dollar weakening, inflation expectations may rise. TIPS offer positive real yields while protecting purchasing power. This adds bond exposure while aligning with the inflationary macro thesis.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "SLV",
      "company_name": "iShares Silver Trust",
      "asset_class": "commodity_etf",
      "sector": "Metals",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "hedge",
      "risk_level": "moderate",
      "time_horizon": "medium_term",
      "allocation_pct": 5,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 73.13,
      "entry_zone": {
        "low": 73.13,
        "high": 76.9
      },
      "price_target": 93.73,
      "stop_loss": 65.2,
      "thesis": "Silver (+8.9% 1mo) is lagging gold's surge (+11.7%), creating catch-up potential in precious metals bull market. Historically, silver outperforms gold in late-stage PM rallies with higher beta. Industrial demand from EV batteries, solar panels, and electronics adds fundamental support beyond monetary demand. Gold-silver ratio likely to compress. Adding to metals complex while maintaining diversification within precious metals exposure.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "TEVA",
      "company_name": "Teva Pharmaceutical Industries Ltd",
      "asset_class": "international_stock",
      "sector": "Healthcare",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "value",
      "risk_level": "moderate",
      "time_horizon": "medium_term",
      "allocation_pct": 5,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 33.08,
      "entry_zone": {
        "low": 33.08,
        "high": 34.78
      },
      "price_target": 43.77,
      "stop_loss": 29.01,
      "thesis": "TEVA just broke to 52-week highs at $34.10, signaling turnaround thesis gaining traction. World's largest generic drug manufacturer with opioid litigation overhang now largely resolved. New CEO executing cost cuts and pipeline revitalization. Trading at significant discount to Viatris and other generics peers. Biosimilar pipeline (Humira, Stelara) provides growth runway. Israeli domicile adds international diversification.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "FDX",
      "company_name": "FedEx Corporation",
      "asset_class": "us_stock",
      "sector": "Industrials",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "garp",
      "risk_level": "moderate",
      "time_horizon": "medium_term",
      "allocation_pct": 5,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 312.61,
      "entry_zone": {
        "low": 312.61,
        "high": 328.73
      },
      "price_target": 387.74,
      "stop_loss": 276.96,
      "thesis": "FDX breaking to 52-week high at $322.28 with industrials sector surging (+5.8% 1mo, RS +5.3). DRIVE transformation program targeting $4B in cost savings beginning to flow through margins. Network consolidation (FedEx Ground/Express merger) creates structural efficiency gains. E-commerce volumes recovering post-destocking. Trading at 14x forward earnings with 15%+ EPS growth potential makes this classic GARP opportunity.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "SONY",
      "company_name": "Sony Group Corporation",
      "asset_class": "international_stock",
      "sector": "Technology",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "value",
      "risk_level": "aggressive",
      "time_horizon": "medium_term",
      "allocation_pct": 5,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 21.43,
      "entry_zone": {
        "low": 21.43,
        "high": 22.54
      },
      "price_target": 28.12,
      "stop_loss": 18.58,
      "thesis": "SONY is extremely oversold (RSI 8.7) presenting contrarian opportunity in diversified tech/entertainment conglomerate. PlayStation 5 installed base growing with strong software attach rates. Image sensor business supplies Apple and automotive (ADAS). Music and pictures segments provide stability. Sony Financial adds recurring income. Japanese yen weakness helps export competitiveness. At <15x earnings, substantial discount to US entertainment/tech peers.",
      "status": "HOLD",
      "last_reviewed": "2026-01-30"
    },
    {
      "ticker": "XEL",
      "company_name": "Xcel Energy Inc.",
      "asset_class": "us_stock",
      "sector": "Utilities",
      "sub_industry": "",
      "market_cap": "",
      "geography": "US",
      "investment_style": "dividend",
      "risk_level": "conservative",
      "time_horizon": "long_term",
      "allocation_pct": 5,
      "shares": 0,
      "recommended_date": "2026-01-30",
      "recommended_price": 73.78,
      "entry_zone": {
        "low": 73.78,
        "high": 77.58
      },
      "price_target": 88.07,
      "stop_loss": 68.05,
      "thesis": "XEL exhibits a golden cross technical pattern signaling momentum shift. As a regulated utility with significant renewable energy exposure (wind, solar), it benefits from electrification tailwinds while providing defensive dividend income (~3.5% yield). In an expensive market with inflationary pressures, utilities offer stability with rate-base growth. The portfolio currently has zero utilities exposure - this fills a critical defensive gap.",
      "status": "BUY",
      "last_reviewed": "2026-01-30"
    }
  ],
  "cash": {
    "allocation_pct": 5,
    "vehicle": "SGOV",
    "yield_pct": 5.1
  },
  "monthly_history": [
    {
      "month": "2026-01",
      "starting_value": 100000,
      "ending_value": 100000.0,
      "portfolio_return_pct": 0.0,
      "sp500_return_pct": 0.16,
      "alpha_pct": -0.16,
      "recommendations_made": [
        {
          "ticker": "GLD",
          "action": "BUY",
          "allocation": 10
        },
        {
          "ticker": "XOM",
          "action": "BUY",
          "allocation": 10
        },
        {
          "ticker": "FCX",
          "action": "BUY",
          "allocation": 7
        },
        {
          "ticker": "KO",
          "action": "BUY",
          "allocation": 10
        },
        {
          "ticker": "ISRG",
          "action": "BUY",
          "allocation": 8
        },
        {
          "ticker": "GSK",
          "action": "BUY",
          "allocation": 8
        },
        {
          "ticker": "BRK-B",
          "action": "BUY",
          "allocation": 10
        },
        {
          "ticker": "TIP",
          "action": "BUY",
          "allocation": 7
        }
      ],
      "sells_executed": [],
      "notable_politician_trades": [
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "LPAB",
          "transaction_type": "Purchase",
          "amount": "$1M-$5M",
          "insight": "Large position in AllianceBernstein - unusual choice suggests confidence in asset management sector or specific knowledge"
        },
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "GOOGL",
          "transaction_type": "Purchase (after selling)",
          "amount": "$500K-$1M",
          "insight": "Sold $1M-$5M then repurchased smaller amounts - may be tax-loss harvesting or repositioning at better price"
        },
        {
          "politician": "Angus King",
          "party": "I",
          "ticker": "LLY",
          "transaction_type": "Purchase",
          "amount": "$1K-$15K",
          "insight": "Healthcare committee insight? LLY is obesity drug leader - may signal confidence in regulatory environment"
        },
        {
          "politician": "Dale Strong",
          "party": "R",
          "ticker": "IREN",
          "transaction_type": "Purchase",
          "amount": "$1K-$15K",
          "insight": "IREN is Bitcoin mining/AI infrastructure - may signal pro-crypto policy expectations"
        }
      ]
    },
    {
      "month": "2026-01",
      "starting_value": 100000,
      "ending_value": 100000.0,
      "portfolio_return_pct": 0.0,
      "sp500_return_pct": 0.65,
      "alpha_pct": -0.65,
      "recommendations_made": [
        {
          "ticker": "SLV",
          "action": "BUY",
          "allocation": 5
        },
        {
          "ticker": "TEVA",
          "action": "BUY",
          "allocation": 5
        },
        {
          "ticker": "FDX",
          "action": "BUY",
          "allocation": 5
        },
        {
          "ticker": "SONY",
          "action": "BUY",
          "allocation": 5
        }
      ],
      "sells_executed": [],
      "notable_politician_trades": [
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "GOOGL",
          "transaction_type": "Purchase",
          "amount": "$500K-$1M",
          "date": "16 Jan 2026",
          "insight": "Pelosi adding to GOOGL despite recent DOJ antitrust headwinds. Either sees resolution or believes AI/Cloud growth outweighs regulatory risk. Her tech timing has historically been prescient."
        },
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "AMZN",
          "transaction_type": "Purchase",
          "amount": "$500K-$1M",
          "date": "16 Jan 2026",
          "insight": "Large AMZN buy following a large sale in December suggests repositioning, not abandonment. May anticipate AWS growth acceleration or retail margin improvement."
        },
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "LPAB",
          "transaction_type": "Purchase",
          "amount": "$1M-$5M",
          "date": "16 Jan 2026",
          "insight": "AllianceBernstein position is notable - asset management play suggests confidence in market rally continuation or potential M&A activity."
        },
        {
          "politician": "Steve Cohen",
          "party": "D",
          "ticker": "NOC",
          "transaction_type": "Sale",
          "amount": "$15K-$50K",
          "date": "29 Dec 2025",
          "insight": "House member selling defense contractor. May signal reduced defense spending expectations or simply profit-taking after strong defense sector run."
        },
        {
          "politician": "Angus King",
          "party": "I",
          "ticker": "LLY",
          "transaction_type": "Purchase",
          "amount": "$1K-$15K",
          "date": "29 Dec 2025",
          "insight": "Independent Senator buying GLP-1 leader Eli Lilly. Obesity drug secular growth thesis remains intact despite recent pullback."
        }
      ]
    },
    {
      "month": "2026-01",
      "starting_value": 100000,
      "ending_value": 100000.0,
      "portfolio_return_pct": 0.0,
      "sp500_return_pct": 0.72,
      "alpha_pct": -0.72,
      "recommendations_made": [
        {
          "ticker": "XEL",
          "action": "BUY",
          "allocation": 5
        }
      ],
      "sells_executed": [],
      "notable_politician_trades": [
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "GOOGL",
          "transaction_type": "Purchase",
          "amount": "$500K-$1M",
          "insight": "Pelosi bought GOOGL options mid-January after selling $1M-$5M in late December. Mixed signals suggest active trading rather than directional conviction. Tech underperformance (-1.05% 1mo) not yet validating the buys."
        },
        {
          "politician": "Nancy Pelosi",
          "party": "D",
          "ticker": "AMZN",
          "transaction_type": "Purchase",
          "amount": "$500K-$1M",
          "insight": "Similar pattern to GOOGL - sold $1M-$5M on Dec 24, repurchased $100K-$500K on Dec 30, added $500K-$1M on Jan 16. Active trading in mega-cap tech despite sector weakness."
        },
        {
          "politician": "Angus King",
          "party": "I",
          "ticker": "LLY",
          "transaction_type": "Purchase",
          "amount": "$1K-$15K",
          "insight": "Small purchase in GLP-1 leader Eli Lilly. Healthcare defensive play aligns with sector outperformance. King sits on Energy and Armed Services committees - no obvious conflict."
        },
        {
          "politician": "Katie Britt",
          "party": "R",
          "ticker": "JPM",
          "transaction_type": "Sale",
          "amount": "$1K-$15K",
          "insight": "Most recent trade (Jan 28) - sold JPMorgan as Financials underperform (-3.15% 1mo). Pattern of selling mega-caps continues."
        }
      ]
    }
  ],
  "closed_positions": [],
  "performance_summary": {
    "total_return_pct": 0.0,
    "sp500_total_return_pct": 1.53,
    "total_alpha_pct": -1.53,
    "win_count": 0,
    "loss_count": 0,
    "win_rate_pct": 0,
    "average_win_pct": 0,
    "average_loss_pct": 0,
    "best_trade": null,
    "worst_trade": null
  }
}